Video Gallery
Features & Benefits
PREDICTABLE
Embosphere Microspheres temporarily compress up to 33% for smooth microcatheter passage. Once through the microcatheter, they return to their original spherical shape and stated diameter for predictable, reliable delivery.1
TARGETED
Embosphere Microspheres show a direct correlation between the level of arterial occlusion and the size of the particles used, allowing for consistent and reliable targeted occlusion.2,3
ESTABLISHED
Embosphere Microspheres are the most clinically studied and clinically utilized spherical embolic, having been proven:
• In over 350,000 procedures4
• With +20 years’ clinical experience4
• In more than 200 clinical articles4
NON-AGGREGATING PROPERTIES
The hydrophilic surface and spherical shape of Embosphere Microspheres prevent aggregation in the catheter lumen and vasculature.
SUPERIOR REBOUND CAPABILITY
Embosphere Microspheres’ elastic properties allow temporary compression of up to 33% to facilitate smooth microcatheter passage (A).1 Once through the microcatheter, Embosphere Microspheres return to their original spherical shape and stated diameter (B) for predictable, targeted delivery.1
DURABLE OCCLUSION
Embosphere Microspheres are biocompatible and nonresorbable with cell adhesion properties that enable complete and durable mechanical occlusion.
Embosphere Microspheres at six months (A) and six years (B) after embolization of facial AVM.
Images courtesy of Dr. Alex Laurent, Hôpital Lariboisière, Paris, France
PERCENTAGE OF PATIENTS WITH COMPLETE INFARCTION RATES OF OVERALL UTERINE FIBROID TUMOR BURDEN
With Embosphere Microspheres, 100% infarction of the entire uterine fibroid tumor burden has been reported in up to 92.3% of patients.
Complete infarction of all fibroids leads to better long-term clinical outcomes, including a higher rate of symptom control and a lower rate of additional gynecologic intervention compared with incomplete infarction of fibroid tissue.8
Leiomyoma infarction above 90% on contrast-enhanced MR images after UAE show significantly better symptom control and fewer reinterventions than patients with a lower infarction rate.9
REFERENCES
1. Laurent, et al. Trisacryl Gelatin Microspheres for Therapeutic Embolization, I: Development and In Vitro Evaluation. Am J Neuroradial. 1996 Mar; 17:533-540
2. Pelage JP, et al. Uterine Artery Embolization in Sheep: Comparison of Acute Effects with Polyvinyl Alcohol Particles and Calibrated Microspheres. Radiol. 2002;224:436-45
3. Verret V, et al. The Arterial Distribution of Embozene and Embosphere Microspheres in Sheep Kidney and Uterus Embolization Models. J Vasc Interv Radiol. 2011 Feb;22(2):220-8
4. Data on file
5. Siskin G, et al. Leiomyoma Infarction after Uterine Artery Embolization: A Prospective Randomized Study Comparing Tris-acryl Gelatin Microspheres versus Polyvinyl Alcohol Microspheres. J Vasc Interv Radiol. 2008; 19:42-46
6. Smeets AJ, et al. Embolization of Uterine Leiomyomas with Polyzene F-coated Hydrogel Microspheres: Initial Experience. J Vasc Interv Radiol. 2010 Dec;21(12):1830-4
7. Chrisman HB, et al., Prospective Evaluation of the Embolic Agent Bead Block in the Treatment of Uterine Leiomyomas with Uterine Artery Embolization. J Vasc Interv Radiol. 2010 Apr;21(4):484-9
8. Katsumori T, et al. Infarction of Uterine Fibroids After Embolization: Relationship Between Postprocedural Enhanced MRI Findings and Long-Term Clinical Outcomes. Cardiovasc Intervent Radiol. 2008;31:66
9: Kroencke TJ, Scheurig C, Poellinger A, Gronewold M, Hamm B. Uterine artery embolization for leiomyomas: percentage of infarction predicts clinical outcome. Radiology. 2010 Jun;255(3):834–41. doi: 10.1148/radiol.10090977. Epub 2010 Apr 14. PMID: 20392986. Uterine artery embolization for leiomyomas: percentage of infarction predicts clinical outcome – PubMed (nih.gov)
409050001_001 ID110124